ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV) announced today that it has signed a licensing and distribution agreement with Essex Bio-Technology Limited, a leading biopharmaceutical drug development and marketing company in the People’s Republic of China, for InSite’s AzaSite® (azithromycin ophthalmic solution) 1%.
